Irish pharma firms took in $1.5 billion across seven deals last year, led higher by the sale of Cathal Friel’s Amryt Pharma The value of merger and acquisition (M&A) transactions

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client. Irish-founded Hvivo runs drug trials known as challenge studies from its London clinics. The company will

Hvivo, the pharmaceutical services company formerly known as Open Orphan, has signed a contract worth £6.3 million (€7.3 million) to test a potential treatment for the common cold. The contract,

London-based CRO hVIVO has landed a £16.8 million ($21 million) contract from an unnamed drugmaker to conduct a phase 2 trial of its respiratory syncytial virus (RSV) antiviral drug candidate. The company, which

Stock market listed pharmaceutical services firm Hvivo has signed a £16.8m (€19.5m) contract with an existing pharmaceutical client. The contract will see Hvivo test the pharmaceutical company’s respiratory syncytial virus